Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals, headquartered in New York, NY, with a team size of 15, operates in the healthcare industry, specifically within drug discovery and delivery. As a participant in the Y-Combinator S20 batch, the company has established itself in both the United States and Canada, offering fully remote work options. Gilgamesh is dedicated to transforming the treatment of mental illnesses by moving beyond symptom management to target the underlying causes of these conditions. Their approach combines advanced medicinal chemistry, intellectual property strategy, neuroscience, neurobiology, and drug development expertise. The company’s research focuses on developing novel chemical entities (NCEs), including NMDAR Antagonists, 5-HT2AR Agonists, and safer Ibogaine Analogs, aimed at addressing depression, opioid abuse disorder, and other mental health issues. Gilgamesh utilizes an AI-powered discovery and translational platform to expedite the development of precision psychiatric therapies. Collaborating with leading research institutions such as Columbia University, NIDA, NYU, and Yale, Gilgamesh is at the forefront of biotech innovation. The company has secured funding from prominent investors like Y Combinator and Prime Movers Lab, raising $39 million in a Series B funding round to further their mission of advancing mental health treatments.